Navigation Links
OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial
Date:9/19/2011

BOTHELL, Wash. and VANCOUVER, British Columbia, Sept. 19, 2011 /PRNewswire/ -- Today OncoGenex (NASDAQ: OGXI) announced that the company has successfully completed an amendment to the approved SPA with the U.S. Food and Drug Administration (FDA) to expand the inclusion criteria for the Prostate Cancer SATURN Clinical Trial - a Phase III study testing whether their experimental drug custirsen, also known as OGX-011/TV-1011, can improve quality of life by reducing cancer pain for more than 12 weeks in men with metastatic castrate-resistant prostate cancer (mCRPC). As part of the approved amendment to the protocol and the SPA, patients may now receive either docetaxel re-treatment or cabazitaxel as second-line taxane chemotherapy. The study design remains the same; all patients must have stable pain at study entry and will be randomized to receive custirsen or placebo in conjunction with taxane chemotherapy.

"Until recently, docetaxel was the only standard of care for chemotherapy treatment of mCRPC with a demonstrated survival benefit," said Dr. Tomasz Beer, the study's principal investigator in the United States.  "With the recent approval of cabazitaxel for mCRPC treatment after docetaxel, men have a new option that extends survival.  In an effort to improve the palliative benefits of this new treatment, we are evaluating custirsen with cabazitaxel for pain palliation. Pain palliation in patients treated with cabazitaxel was reported at 9.2% and pain is one of the most common and devastating consequences of very advanced prostate cancer."

Custirsen is an experimental drug that is designed to block the production of a protein that is associated with treatment resistance in many cancers. In Phase II trials, custirsen combined with docetaxel as either first-line or second-line chemotherapy showed a 6.9 month improvement in overall survival over doc
'/>"/>

SOURCE OncoGenex Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
2. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
3. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
4. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
5. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Inc., a leader in hand hygiene monitoring, today announced ... subsidiary of Ascendis Health Limited, in Johannesburg, ... of millions of patients around the world are affected ... patient to patient via the unwashed hands of healthcare ...
(Date:1/23/2015)... 2015   Leatt Corporation  (OTCQB: LEAT), a global developer, ... forms of sports, including extreme motor sports, and whose ... that the UISP Lega Motociclismo Lombardia, an Italian motocross ... wear a neck brace during its racing competitions.  ...
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE ... specializes in the development and sale of patented biopharmaceutical ... active pharmaceutical ingredients (API) today announced the business and ... operation. 1. Following the September 2014 JCM ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... annual revenues in the past three years. Today, the business ... , According to the sales manager of the company, this ... in 2015. This point can be reflected on the discounted ...
(Date:1/22/2015)... Four years since the release of their debut recording Love is ... Avasa & Matthew Love – the duo are pleased to announce ... White Swan Records on February 24, 2015. , THE ROAD offers ... to all of us to walk out of the mire of ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the ... an effort to further promote visibility and adoption of the ... made AMA journals available via its subscription services, EBSCO will ... , Long known as both a subscription agency ...
(Date:1/22/2015)... is a famous dress online store for wedding dresses and ... collection of wedding dresses , and launches a site-wide women’s ... dress on your big day; the wedding gown is the ... to find the most suitable wedding dress. Now, we are ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... ... Today 5,000 Nurses at 11 ... In an atmosphere that nurses,describe as attempted "intimidation" from Sutter ... authorize,their bargaining teams to strike the hospital chain for up to ...
... March 3 To help mark National,Patient Safety Awareness ... to be an active partner in their own health ... in their own medicine cabinet.,The theme of this year,s ... Road Taken Together," and the AMA is offering easy ...
... March 3 Today AXA Equitable,unveiled its new ... product, designed to deliver cost-effective death benefit,protection to ... and,charitable planning needs. By providing a death benefit ... III can be used to pay sizeable estate,taxes ...
... For the first,time, Beauty.com, Inc., a wholly owned ... Los Angeles-based women,s wear designer Jenni,Kayne to create a ... clutch. Customers receive the limited edition designer bag,filled with ... beauty,brands with a purchase of $75 or more on ...
... TEWKSBURY, Mass. and MEMPHIS, Tenn., March 3 ,Comprehensive ... of Public Health (DPH)/State Office for Pharmacy,Services (SOPS) ... of,February 2008. CPS will provide state- of-the-art pharmacy ... the Commonwealth. SOPS,chose CPS to replace its current ...
... Has Ranked on the FORTUNE ... Survey, ... again. In its 2008 annual survey, FORTUNE,magazine ranked the company as "America,s Most ... the,only company to have led its industry every year it has been included ...
Cached Medicine News:Health News:In Face of Hostile Bargaining and Intimidation by Management, Mills-Peninsula to Vote to Authorize Strike 2Health News:In Face of Hostile Bargaining and Intimidation by Management, Mills-Peninsula to Vote to Authorize Strike 3Health News:AMA Asks Patients: Do You Know What's in Your Medicine Cabinet? 2Health News:AXA Equitable Meets the Needs of Two People under One Life Insurance Policy 2Health News:AXA Equitable Meets the Needs of Two People under One Life Insurance Policy 3Health News:Beauty.com Partners With Fashion Designer Jenni Kayne 2Health News:Beauty.com Partners With Fashion Designer Jenni Kayne 3Health News:Beauty.com Partners With Fashion Designer Jenni Kayne 4Health News:Comprehensive Pharmacy Services Awarded $80 Million Dollar Pharmacy Services Contract for the State of Massachusetts 2Health News:Comprehensive Pharmacy Services Awarded $80 Million Dollar Pharmacy Services Contract for the State of Massachusetts 3Health News:Northwestern Mutual Is 'America's Most Admired' for an Unprecedented 25th Year 2
Calibration Plasmas for Assaysof Unfractionated Heparins (UFH) using the Anti-Xa Method on STA© Analyzers....
Control Plasma for Assays of Low MolecularWeight Heparins (LMWH) using Anti-Xa Method on STA© Analyzers....
Multi-constituent normal and abnormal plasma controls for routine and specialty assays performed on the STA© family of hemostasis analyzers....
PT, PTT, Fibrinogetn & TT Normal and Abnormal Controls...
Medicine Products: